Progress in basic inflammatory bowel disease research

Seminars in Pediatric Surgery

Volumn 16, Issue 3, 2007, Pages 146-153

  Kugathasan, Subra ^a   Fiocchi, Claudio ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Crohn's disease; Environment; Genetic susceptibility; Gut flora; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ARTICLE; BASIC RESEARCH; ENTERITIS; ENVIRONMENTAL FACTOR; GENOMICS; HEREDITY; HUMAN; IMMUNOREACTIVITY; INTESTINE FLORA; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEOMICS; TISSUE INJURY;

ADOLESCENT; ADULT; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; INTESTINAL MUCOSA; RISK FACTORS;

EID: 34250804761     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2007.04.002     Document Type: Article

References (85)

1. Cobrin G.M., and Abreu M.T. Defects of mucosal immunity leading to Crohn's disease. Immunol Rev 206 (2005) 277-295
2. Targan S.R., and Karp L.C. Defects of mucosal immunity leading to ulcerative colitis. Immunol Rev 206 (2005) 296-305
3. Bousvaros A., Sylvester F., Kugathasan S., et al. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis 12 (2006) 886-913
4. Cohen M.L. Changing patterns of infectious disease. Nature 406 (2000) 762-767
5. Ouyang Q., Tandon R., Goh K.-L., et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 21 (2005) 408-413
6. Bach J.-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (2002) 911-920
7. Danese S., Sans M., and Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmunity Rev 3 (2004) 390-400
8. Thomas G.A.O., Rhodes J., and Green J.T. Inflammatory bowel disease and smoking: a review. Am J Gastroenterol 93 (1998) 144-149
9. Timmer A., Sutherland L.R., and Martin F. Oral contraceptive use and smoking are risk factors for relapse of Crohn's disease. Gastroenterology 114 (1998) 1143-1150
10. Rutgeerts P., D'Haens G., Hiele M., et al. Appendectomy protects against ulcerative colitis. Gastroenterology 106 (1994) 1251-1253
11. Andersson R.E., Olaison G., Tysk C., et al. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 124 (2003) 40-46
12. Hugot J.-P., Chamaiilard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
13. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in Nod2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
14. Chamaillard M., Iacob R., Desreumaux P., et al. Advances and perspectives in the genetics of inflammatory bowel disease. Clin Gastroenterol Hepatol 4 (2006) 143-151
15. Giallourakis C., Stoll M., Miller K., et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and indentification of a novel association with ulcerative colitis. Am J Hum Genet 73 (2003) 205-211
16. Negoro K., McGovern D.P., Kinouchi Y., et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn's disease. Gut 52 (2003) 541-546
17. Babusukumar U., Wang T., McGuire E., et al. Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn's disease. Am J Gastroenterol 101 (2006) 1-8
18. Stoll M., Corneliussen B., Costello C.M., et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36 (2004) 476-480
19. Friedrichs F., Brescianini S., Annese V., et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum Genet 119 (2006) 305-311
20. Panwala C.M., Jones J.C., and Viney J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resitance gene, mdr1a, spontaneously develop colitis. J Immunol 161 (1998) 5733-5744
21. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
22. Becker C., Wirtz S., Blessing M., et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112 (2003) 693-706
23. Oppmann B., Lesley R., Blom B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000) 715-725
24. Abreu M.T., Taylor K.D., Ling Y.C., et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123 (2002) 679-688
25. Kugathasan S., Collins N., Maresso K., et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 1003-1009
26. Kobayashi K.S., Chamaillard M., Ogura Y., et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
27. Chiodini R.J., Kruiningen H.J.V., Thayer W.R., et al. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 29 (1984) 1073-1079
28. Thomas G.A.O., Swift G.L., Green J.T., et al. Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut 42 (1998) 497-500
29. Darfeuille-Michaud A., Neut C., Barnich N., et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115 (1998) 1405-1413
30. Wakefield A.J., Pittilo R.M., Sim R., et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 39 (1993) 345-353
31. Ekbom A., Daszak P., Kraaz W., et al. Crohn's disease after in-utero measles virus exposure. Lancet 348 (1996) 515-517
32. MacDonald T.T., and Monteleone G. Immunity, inflammation, and allergy in the gut. Science 307 (2005) 1920-1925
33. Strober W., Fuss I.J., and Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 20 (2002) 495-549
34. Swidsinski A., Ladhoff A., Pernthaler A., et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122 (2002) 44-54
35. D'Haens G., Geboes K., Peeters M., et al. Early lesions caused by infusion of intestinal contents in excluded ileum of Crohn's disease. Gastroenterology 114 (1998) 262-267
36. Campieri M., and Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?. Gastroenterology 116 (1999) 1246-1260
37. Targan S.R., Landers C.J., Yang H., et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128 (2005) 2020-2028
38. Duchmann R., Kaiser I., Hermann E., et al. Tolerance exists towards resident intestinal flora but it is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102 (1995) 448-455
39. Kelly D., Conway S., and Aminov R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol 26 (2005) 326-333
40. Girardin S.E., Hugot J.-P., and Sansonetti P.J. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol 24 (2003) 652-658
41. Fiocchi C. The normal intestinal mucosa: a state of "controlled inflammation.". In: Targan S.R., and Shanahan F. (Eds). Inflammatory Bowel Disease. From Bench to Bedside. (2nd ed.) (2003), Kluwer Academic Publishers, Dordrecht 101-120
42. Hisamatsu T., Suzuki M., Reinecker H.-C., et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124 (2003) 993-1000
43. Staag A.J., Hart A.L., Knight S.C., et al. The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. Gut 52 (2003) 1522-1529
44. Hart A.L., Al-Hassi H.O., Rigby R.J., et al. Characteristics of intestinal dendritic cells in inflammatory bowel disease. Gastroenterology 129 (2005) 50-65
45. Wehkamp J., Harder J., Weichenthal M., et al. NOD2(CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 53 (2004) 1658-1664
46. Wehkamp J., Harder J., Weichenthal M., et al. Inducible and constitutive β-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 9 (2003) 215-223
47. Cook D.N., Pisetsky D.S., and Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5 (2004) 975-979
48. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
49. Cario E., and Podolsky D.K. Differential alterationin intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68 (2000) 7010-7017
50. Franchimont D., Vermeire S., ElHousni H., et al. Deficient host-bacteria interactions in inflammatory bowel disease?. The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
51. Torok H.-P., Glas J., Tonenchi L., et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 127 (2004) 365-366
52. Li J., Moran T., Swanson E., et al. Regulation of IL-8 and IL-1β expression in Crohn's disease associated with NOD2/CARD15 mutations. Hum Mol Genet 13 (2004) 1715-1725
53. van Heel D.A., Gosh S., Butler M., et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365 (2005) 1794-1796
54. Takahashi F., and Das K.M. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest 76 (1985) 311-318
55. Podolsky D.K., and Fiocchi C. Cytokines, chemokines, growth factors, eicosanoids and other bioactive molecules in IBD. In: Kirsner J.B. (Ed). Inflammatory Bowel Disease (1999), W.B. Saunders, Philadelphia, PA 191-207
56. Neurath M.F., Weigmann B., Finotto S., et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195 (2002) 1129-1143
57. Monteleone G., Biancone L., Marasco R., et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112 (1997) 1169-1178
58. Pizarro T.P., Michie M.H., Bentz M., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 162 (1999) 6829-6835
59. Ina K., Itoh J., Fukushima K., et al. Resistance of Crohn's disease T-cells to multiple apoptotic stimuli is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 163 (1999) 1081-1090
60. Sturm A., Leite A.Z., Danese S., et al. Divergent cell cycle kinetic sunderlie the distinct functional capacity of mucosal T-cells in Crohn's disease (CD) and ulcerative colitis (UC). Gut 53 (2004) 1624-1631
61. Fuss I.J., Neurath M., Boirivant M., et al. Disparate CD4+ lamina propria lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 (1996) 1261-1270
62. Fuss I.J., Heller F., Boirivant M., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113 (2004) 1490-1497
63. Weaver C.T., Harrington L.E., Mangan P.R., et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
64. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116 (2006) 1218-1222
65. Yen D., Cheung J., Scheerens H., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
66. Fujino S., Andoh A., Bamba S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
67. high T cells in inflammatory bowel disease. Gastroenterology 128 (2005) 1868-1878
68. bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 173 (2004) 3119-3130
69. Selby W.S., Janossy G., Mason D.Y., et al. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 53 (1983) 614-618
70. Mayer L., and Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 86 (1990) 1255-1260
71. Nakazawa A., Dotan I., Brimnes J., et al. The expression and function of costimulatory molecules B7h and B7-H1 on colonic epithelial cells. Gastroenterology 126 (2004) 1347-1357
72. Baugh M.D., Perry M.J., Hollander A.P., et al. Matrix metalloproteinases levels are elevated in inflammatory bowel disease. Gastroenterology 117 (1999) 814-822
73. Monteleone G., MacDonald T.T., Wathen N.C., et al. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 117 (1999) 1069-1077
74. Vogel J.D., West G.A., Sturm A., et al. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines causing T-cell transmigration. Gastroenterology 126 (2004) 63-80
75. Binion D.G., West G.A., Volk E.E., et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 352 (1998) 1742-1746
76. Binion D.G., Rafiee P., Ramunujam K.S., et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radical Biol Med 29 (2000) 881-888
77. Weyrich A.S., and Zimmerman G.A. Platelets: signaling cells in the immune continuum. Trends Immunol 25 (2004) 489-495
78. Danese S., Katz J.A., Saibeni S., et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52 (2003) 1435-1441
79. Danese S., delaMotte C., Sturm A., et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124 (2003) 1249-1264
80. Danese S., Sans M., delaMotte C., et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130 (2006) 2060-2073
81. Korzenik J.R. Past and current theories of etiology of IBD. Toothpaste, worms, and refrigerators. J Clin Gastroenterol 39 suppl 2 (2005) S59-S65
82. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 20 (2004) 311-317
83. Rufo P.A., and Bousvarors A. Current therapy of inflammatory bowel disease in children. Pediatr Drugs 8 (2006) 279-302
84. Sandborn W.J., and Targan S.R. Biological therapy of inflammatory bowel disease. Gastroenterology 122 (2002) 1592-1608
85. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633